Characterization of the cellular localization, expression level, and function of SNP variants of MRP2/ABCC2

被引:85
作者
Hirouchi, M
Suzuki, H
Itoda, M
Ozawa, S
Sawada, J
Ieiri, I
Ohtsubo, K
Sugiyama, Y [1 ]
机构
[1] Univ Tokyo, Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan
[2] Natl Inst Hlth Sci, Setagaya Ku, Tokyo 1588501, Japan
[3] Tottori Univ, Fac Med, Dept Hosp Pharm, Tottori 6838504, Japan
关键词
biliary excretion; Dubin-Johnson syndrome; MRP2/ABCC2; SNPs;
D O I
10.1023/B:PHAM.0000026422.06207.33
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. The presence of single nucleotide polymorphisms ( SNPs) has been reported for multidrug resistance-associated protein 2 (MRP2/ABCC2). The purpose of the current study was to characterize the localization, expression level, and function of MRP2 variants. Methods. The expression and cellular localization of the wild-type and three kinds of reported SNP variants of MRP2 molecules were analyzed in LLC-PK1 cells after infection with the recombinant Tetoff adenoviruses. Their function was determined by using the isolated membrane vesicles from the infected LLC-PK1 cells. Results. The transport activity for E(2)17betaG, LTC4, and DNP-SG, normalized by the expression level of MRP2, was similar between the wild-type, V417I, and A1450T MRP2s. The transport activity of S789F MRP2 was slightly higher than that of wild-type MRP2. However, the expression level of S789F and A1450T MRP2 proteins was significantly lower compared with the wild-type and V417I MRP2. In addition, although the wild-type and V417I MRP2 were exclusively localized in the apical membrane, S789F and A1450T MRP2 were located in the apical membrane and also in the intracellular compartment. Conclusions. These results suggest that the most frequently observed V417I substitution may not affect the in vivo function of MRP2, whereas the much less frequently observed S789F and A1450T may be associated with the reduced in vivo function.
引用
收藏
页码:742 / 748
页数:7
相关论文
共 30 条
[1]   Cytochromes P450 and metabolism of xenobiotics [J].
Anzenbacher, P ;
Anzenbacherová, E .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2001, 58 (5-6) :737-747
[2]   Mammalian ABC transporters in health and disease [J].
Borst, P ;
Elferink, RO .
ANNUAL REVIEW OF BIOCHEMISTRY, 2002, 71 :537-592
[3]  
Cui YH, 1999, MOL PHARMACOL, V55, P929
[4]   Increased bioavailability of the food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in MRP2-deficient rats [J].
Dietrich, CG ;
De Waart, DR ;
Ottenhoff, R ;
Schoots, IG ;
Elferink, RPJO .
MOLECULAR PHARMACOLOGY, 2001, 59 (05) :974-980
[5]  
Elferink RO, 2002, BBA-MOL BASIS DIS, V1586, P129
[6]   Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA [J].
Evers, R ;
Kool, M ;
van Deemter, L ;
Janssen, H ;
Calafat, J ;
Oomen, LCJM ;
Paulusma, CC ;
Elferink, RPJO ;
Baas, F ;
Schinkel, AH ;
Borsi, P .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (07) :1310-1319
[7]   The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans [J].
Fromm, MF .
ADVANCED DRUG DELIVERY REVIEWS, 2002, 54 (10) :1295-1310
[8]   Clinical relevance of genetic polymorphisms in the human CYP2C subfamily [J].
Goldstein, JA .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 52 (04) :349-355
[9]  
Gotoh Y, 2000, J PHARMACOL EXP THER, V292, P433
[10]   Trafficking and functional defects by mutations of the ATP-binding domains in MRP2 in patients with Dubin-Johnson syndrome [J].
Hashimoto, K ;
Uchiumi, T ;
Konno, T ;
Ebihara, T ;
Nakamura, T ;
Wada, M ;
Sakisaka, S ;
Maniwa, F ;
Amachi, T ;
Ueda, K ;
Kuwano, M .
HEPATOLOGY, 2002, 36 (05) :1236-1245